rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken
Aandeel

Galapagos BE0003818359

Laatste koers (eur)

22,080

  • Verschil

    -0,200 -0,90%

  • Volume

    65.330 Gem. (3M) 112,4K

  • Bied

    -  

  • Laat

    -  
+ In watchlist

Inhoudelijk Toledo Draadje

475 Posts
Pagina: «« 1 ... 19 20 21 22 23 24 »» | Laatste | Omlaag ↓
  5. Lama Daila 19 april 2021 13:09

    • Lama Daila

      Lid sinds: 11 aug 2015

      Laatste bezoek: 27 apr 2023

    • Aanbevelingen

      Ontvangen: 2112

      Gegeven: 158

    •    Aantal posts: 707

    Tijd voor wat educatie :)

    TAPINOMA wordt ook wel “draaigatje” genoemd

    nl.wikipedia.org/wiki/Mediterraan_dra...

    De benaming draaigatje komt van de door de mier toegepaste manier van verdedigen: eerst bijten en dan het achterlijf naar de wond draaien en er een irriterende stof in spuiten.
  8. Wall Street Trader 30 april 2021 10:44

    • Wall Street Trader

      Lid sinds: 09 aug 2018

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 3455

      Gegeven: 1213

    •    Aantal posts: 1.253

    Gilead Sciences (GILD) Q1 2021 Earnings Call Transcript

    GILD earnings call for the period ending March 31, 2021.

    Galapagos SIK2/3 Toledo proof-of-concept trials across psoriasis, ulcerative colitis, and RA are expected to have readouts later this year.

    Our next question comes from Matthew Harrison with Morgan Stanley.

    Matthew Harrison -- Morgan Stanley -- Analyst

    Great. Good afternoon. Thanks for taking the question. A question on Galapagos, and I guess there are two parts here.

    First part is, you know, you've got these upcoming Toledo readouts. Merdad, maybe you could just comment on what you're potentially looking to see from those readouts, given that the duration of those trials is fairly short. So maybe what you would view as sort of a positive outcome. And then I guess second question is a more sort of broader strategic question here.

    But if you don't see something that's positive out of those, you know, how do you think about the longer-term relationship there? And given that you're the largest shareholder, you know, what might you consider in terms of that relationship?

    Merdad Parsey -- Chief Medical Officer

    Yes, sure. It's a great question. And I think you -- Matthew, you mentioned, I think, look, where we are now with the Toledo programs is looking for evidence of tolerability and proof-of-concept, proof of principle for that pathway in multiple indications. And I would describe these early small studies as a place to demonstrate that and look to see where the biggest impact could be.

    I think it's an early part of the longer journey, ranging from -- you know, is there a particular indication that we want to pursue further to confirm and expand on the signal to -- you know, do we have the right molecule for that. So I think we view these, together with Galapagos, I believe, we view these as sort of very early in the story of the Toledo program. So we'll be looking to see what those data look like in the near term. Dan, do you want add?

    Daniel O'Day -- Chairman and Chief Executive Officer

    Sure. So maybe just to you, Matthew, to just give a little bit of context of people that may not be completely familiar with our relationship with Galapagos. So of course, there was the filgotinib relationship, but then there was a separate relationship that we went into. As you know, a couple of years ago now.

    And that was really based on the research platform. And I would say that nothing has really changed in relation to that. I mean one of the reasons to do that was to diversify our approaches from a discovery research perspective across, if you like, the Gilead Group. I listened hard to the scientists at that time.

    I continue to listen hard to the scientists today. They think they have a very discriminated platform for screening compounds for first-in-class. And I'll remind you, that's really the approach first-in-class, which, of course, comes with some risks, some of which we've seen in the later-stage programs. And of course, Toledo is the most advanced now of those programs.

    But having said that, there are many others within their discovery platform that we continue to be intrigued about. I think it's an important part of our overall inflammation strategy, albeit at an earlier stage for Gilead. But when we think about our strategic approach that really focuses on immunology and virology as our core scientific skills, we have now obviously leaders in virology built up a really significant presence in oncology with inflammatory disorders, really kind of the next step and the next stage of our platform where Galapagos presents, I think one aspect of that, but a very important aspect in terms of first-in-class approach. So we continue to be working very closely with our partners at Galapagos to determine what the next screens are and what the next targets are in the concept of our -- the entirety of our inflammation strategy.

    So thanks, Matt.

    Inflammatory Diseases Pipeline (Pipeline shown below as of end of Q121)
    Bijlage:
  9. Lama Daila 6 mei 2021 21:29

    • Lama Daila

      Lid sinds: 11 aug 2015

      Laatste bezoek: 27 apr 2023

    • Aanbevelingen

      Ontvangen: 2112

      Gegeven: 158

    •    Aantal posts: 707

    quote:

    Wall Street Trader schreef op 20 februari 2021 17:41:

    Thanks to pate

    Salt-inducible kinases are required for the IL-33-dependent secretion of cytokines and chemokines in mast cells

    16 February 2021

    Interestingly, the biotechnology company Galapagos disclosed on October 27th 2020 that compounds from their “Toledo” programme, target the SIK family of protein kinases and that a dual SIK2/SIK3 inhibitor GLPG3970 had passed Phase I trials and would soon be entering advanced clinical trials for Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis. The present study, which shows that the combined inhibition of SIK2/3 suppresses the production of a number of cytokines and chemokines that contribute to the pathogenesis of asthma now suggests that GLPG3970 and/or related compounds may be worth exploring as potential treatments for asthma patients who are refractory to the corticosteroid therapies that are in widespread use.

    www.sciencedirect.com/science/article...

    Zelfde artikel (in meer leesbare layout) van University of Dundee:
    discovery.dundee.ac.uk/ws/portalfiles...

    “Our results suggest that dual inhibitors of SIK2 and SIK3 may have therapeutic potential for the treatment of mast cell–driven diseases.”

    GLPG3970 zou dus mogelijk ook wel eens kunnen werken tegen asthma, of andere mast cell-driven diseases.
  10. Lama Daila 6 mei 2021 22:18

    • Lama Daila

      Lid sinds: 11 aug 2015

      Laatste bezoek: 27 apr 2023

    • Aanbevelingen

      Ontvangen: 2112

      Gegeven: 158

    •    Aantal posts: 707

    quote:

    Lama Daila schreef op 26 maart 2021 07:36:

    [...]

    In de webcast van Piet met Morgan Stanley verduidelijkt Pïet dat GLPG4876 een backup is voor GLPG3970 en dat er momenteel weinig of geen plannen zijn met GLPG4876

    morganstanley.webcasts.com/viewer/eve...
    Q1 2021: We selected an additional molecule from our Toledo program, SIK2/3 inhibitor ‘4876, as a candidate to accelerate from preclinical phase into clinical development;

    Backup voor GLPG3970 die uit de schuif gehaald wordt??

  13. Wall Street Trader 10 mei 2021 21:27

    • Wall Street Trader

      Lid sinds: 09 aug 2018

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 3455

      Gegeven: 1213

    •    Aantal posts: 1.253

    A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate (LADYBUG)

    Recruitment Status : Completed
    First Posted : October 8, 2020
    Last Update Posted : May 10, 2021

    clinicaltrials.gov/ct2/show/NCT04577781
  14. forum rang 5 Endless 11 mei 2021 08:38

    • Endless

      Lid sinds: 06 jan 2015

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 2797

      Gegeven: 2198

    •    Aantal posts: 5.999

    quote:

    Wall Street Trader schreef op 10 mei 2021 21:27:

    A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate (LADYBUG)

    Recruitment Status : Completed
    First Posted : October 8, 2020
    Last Update Posted : May 10, 2021

    clinicaltrials.gov/ct2/show/NCT04577781

    De data zijn dus bekend hopelijk snel geëvalueerd gezien de kleine aantal deelnemers.
  15. Lama Daila 28 mei 2021 20:22

    • Lama Daila

      Lid sinds: 11 aug 2015

      Laatste bezoek: 27 apr 2023

    • Aanbevelingen

      Ontvangen: 2112

      Gegeven: 158

    •    Aantal posts: 707

    Kleine nieuwe Toledo study met GLPG3970:
    clinicaltrials.gov/ct2/show/NCT04907149

    Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970

    6 personen, Completion date Juni 21

    A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Metabolism of GLPG3970 in Healthy Male Subjects Following a Single Oral Dose of GLPG3970 Relative to an Intravenous [14C]GLPG3970 Microtracer and Single Oral [14C]GLPG3970 Administration

    Drug: GLPG3970 film-coated tablet
    Participants will receive a single oral dose of GLPG3970.

    Drug: [14C]GLPG3970 solution for infusion
    Participants will receive an i.v. microtracer microdose.

  16. Loureiro 20 juni 2021 21:12

    • Loureiro

      Lid sinds: 30 sep 2010

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 653

      Gegeven: 504

    •    Aantal posts: 4.194

    quote:

    Wall Street Trader schreef op 10 mei 2021 21:27:

    A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate (LADYBUG)

    Recruitment Status : Completed
    First Posted : October 8, 2020
    Last Update Posted : May 10, 2021

    clinicaltrials.gov/ct2/show/NCT04577781

    Hoe zit het eigenlijk met het onderzoek in UC : had toch ook al completed moeten zijn?????
  17. MtBaker 21 juni 2021 08:44

    • MtBaker

      Lid sinds: 22 dec 2006

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 658

      Gegeven: 1467

    •    Aantal posts: 7.819

    quote:

    abelheira schreef op 20 juni 2021 21:12:

    [...]
    Hoe zit het eigenlijk met het onderzoek in UC : had toch ook al completed moeten zijn?????
    zie iets hoger 6 mei dus
  18. Loureiro 21 juni 2021 09:59

    • Loureiro

      Lid sinds: 30 sep 2010

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 653

      Gegeven: 504

    •    Aantal posts: 4.194

    quote:

    MtBaker schreef op 21 juni 2021 08:44:

    [...]zie iets hoger 6 mei dus
    Enrollment is completed maar onderzoek zou ook al completed moeten zijn.
  19. forum rang 4 Down the drain 2 21 juni 2021 10:05

    • Down the drain 2

      Lid sinds: 01 okt 2020

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 546

      Gegeven: 42

    •    Aantal posts: 1.333

    quote:

    abelheira schreef op 21 juni 2021 09:59:

    [...]
    Enrollment is completed maar onderzoek zou ook al completed moeten zijn.
    Op 4 mei al een publicatie over fase 3 in The Lancet verschenen.
  20. [verwijderd] 21 juni 2021 10:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Down the drain 2 schreef op 21 juni 2021 10:05:

    [...]

    Op 4 mei al een publicatie over fase 3 in The Lancet verschenen.
    Het gaat over Toledo, niet over de Ph 3 studie met Filgotinib in UC.
    Die is in The Lancet verschenen laatst.

    De 3970 studie in UC was mid april 'completed enrollment' --> Active, not recruiting dus.
    Wil zeggen 6 weken extra + 2 weken follow up --> mid juni completed studie.
    Tenminste indien de timings op clinical trials kloppen wat niet altijd het geval is.

    Vaak worden die ook pas een maand later bijgewerkt (zie eerdere studies met 3970, 3667 en Filgotinib). Studie is dus completed nu, maar moet nog aangepast worden op clinical trials, in juli zouden de eerste drie POC's hiervan uitlezen.
  21. forum rang 6 de tuinman 21 juni 2021 14:54

    • de tuinman

      Lid sinds: 15 dec 2009

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 4030

      Gegeven: 2223

    •    Aantal posts: 12.839

    quote:

    Down the drain 2 schreef op 21 juni 2021 10:05:

    [...]

    Op 4 mei al een publicatie over fase 3 in The Lancet verschenen.
    Je weet ook echt niet waar het over gaat, of wel?
475 Posts
Pagina: «« 1 ... 19 20 21 22 23 24 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in
Galapagos

Van de redactie

  1. 10 afgeprijsde aandelen van topbedrijven
  2. Met deze ETF kleurt uw portefeuille groen als de S&P 500 daalt
  3. 7 koopwaardige aandelen voor de lange termijn
  4. Dit aandeel is toegevoegd aan favorietenlijstje beleggers
  5. TA-column Nico Bakker: koopkansen bij Nvidia?
  6. Twee groeiaandelen met verdubbelpotentieel in vijf jaar
Meer artikelen